title: Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.
abstract: OBJECTIVE
  Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control and cardiometabolic risk factors in adults with type 2 diabetes mellitus, but pediatric data is sparse.
  
  
  METHODS
  This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m2) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.
  
  
  RESULTS
  Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.
  
  
  CONCLUSIONS
  Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.
authors.affiliation: Department of Pediatrics, Division of Pediatric Endocrinology, Columbia University Medical Center, USA.
authors.forename: Marisa
authors.initials: M
authors.lastname: Censani
authors.affiliation: Department of Pediatrics, Division of Pediatric Endocrinology, Columbia University Medical Center, USA.
authors.forename: Vivian L
authors.initials: VL
authors.lastname: Chin
authors.affiliation: Department of Pediatrics, Division of Pediatric Endocrinology, Columbia University Medical Center, USA.
authors.forename: Ilene
authors.initials: I
authors.lastname: Fennoy
keywords: Adolescents; Exenatide; Obesity; Type 2 diabetes